Group 1 - The company announced a board meeting on September 26, 2025, to propose the adoption of the 2025 A-share incentive plan and the issuance of restricted shares under this plan [1][2] - The company plans to adopt the assessment management measures for the 2025 A-share incentive plan and authorize the board to handle related matters [1][2] - The company will also propose the adoption of the 2025 H-share option plan and authorize the board to manage related matters [1][2] Group 2 - The company intends to grant H-share options to Dr. Xuefeng YU, totaling 371,300 options [2] - The company will propose the cancellation of repurchased A-shares and a reduction in registered capital [1][2]

智通财经APP讯，康希诺生物(06185)发布公告，董事会于2025年9月26日举行的董事会会议上议决建议 (i)采纳2025年A股激励计划及建议根据2025年A股激励计划发行限制性股票;(ii)采纳2025年A股激励计划 考核管理办法;(iii)授权董事会处理2025年A股激励计划相关事项;(iv)采纳2025年H股购股权计划;(v)授权 董事会处理2025年H股购股权计划相关事项;(vi)建议根据2025年H股购股权计划授予H股购股权;及(vii)注 销购回A股及减少注册资本，所有上述事项均须于临时股东大会上以特别决议案方式获股东批准(惟根 据2025年H股购股权计划向朱涛博士、Shou Bai CHAO博士及Dongxu QIU博士授出H股购股权除外)。 公司将召开临时股东大会，以考虑及酌情批准（其中包括）(i)建议采纳2025年A股激励计划及根据2025 年A股激励计划建议发行限制性股票；(ii)建议采纳2025年A股激励计划考核管理办法；(iii)建议授权董 事会处理2025年A股激励计划相关事项；(iv)建议采纳2025年H股购股权计划；(v)建议授权董事会处理 2025年H股购股权计划相关事项； ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） (1)建議採納2025年A股激勵計劃 董 事 會（不 包 括 須 放 棄 投 票 之 董 事）欣 然 宣 佈，董 事 會 於2025年9月26日舉行之 董事會會議上議決建議(i)採 納2025年A股激勵計劃及建議根據2025年A股激勵 計劃發行限制性股票；(ii)採 納2025年A股激勵計劃考核管理辦法；(iii)授權董 事會處理2025年A股 激 勵 計 劃 相 關 事 項；(iv)採 納2025年H股 購 股 權 計 劃；(v) 授權董事會處理2025年H股 購 股 權 計 劃 相 關 事 項；(vi)建議根據2025年H股 購 股權計劃授予H股 購 股 權；及(vii)註銷購回A股 及 減 少 註 冊 資 本，所 有 上 述 事 項 均 須 於 臨 時 股 東 大 ...

Group 1 - Baiyun Airport announces joint investment with China Duty Free Group to establish a duty-free company with a registered capital of 45 million yuan, where China Duty Free Group holds 51% [3] - Dongxing Medical plans to acquire 90% stake in Wuhan Yijiaobao, a high-tech company focused on orthopedic and biomedical materials [4] - Fosun Pharma's subsidiary plans to transfer 100% stake in Shanghai Clone to enhance asset operation efficiency, with a transaction value of up to 1.256 billion yuan [5] Group 2 - Hengxing Technology's subsidiary is awaiting approval for the extension of mining license for Longtoushan Gold Mine, with exploration activities ongoing [6] - New Sai Co. announces resignation of its general manager Chen Jianjiang due to work adjustments [7] - Hailiang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange, with details yet to be finalized [8] Group 3 - Zhejiang University Network plans to sell 48.6 million shares of Wanliyang, expecting a transaction amount of 475 million yuan [9] - Huazhong Precision terminates the issuance of A-shares to specific targets, affecting a control acquisition [10] - Jiaze New Energy states that its green chemical business is not yet commercially viable, with no significant impact on revenue or profit in the short term [11] Group 4 - Hailan Home plans to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries [12] - Hongfuhang intends to invest up to 1.128 billion yuan in a joint venture to build a photovoltaic energy storage project in Congo [13] - Zhongchuang Zhiling plans to invest 5 billion yuan in a new energy vehicle parts industrial base and R&D center [14] Group 5 - Haitai Development's subsidiary signs a property sale contract worth 440 million yuan, expected to increase profits by approximately 62.86 million yuan in 2025 [15] - Dongjie Intelligent's overseas subsidiary secures a procurement order worth approximately 180 million yuan, representing 22.3% of its audited revenue for 2024 [17] - Zhiguang Electric's subsidiary signs a procurement contract worth 164 million yuan for energy storage systems [18] Group 6 - ST Songfa's subsidiary signs a shipbuilding contract for four VLCCs, with a contract value between 400 million to 600 million USD [19] - Huaguang Huaneng signs a sales contract for waste heat boilers worth 160 million yuan for a power plant project in Cambodia [20] - Yousheng Co. receives a project notification from a German automaker, with total sales expected to reach approximately 2.3 billion yuan [24] Group 7 - Zai Sheng Technology's controlling shareholder plans to reduce holdings by up to 3% [25] - Compton plans to reduce holdings of repurchased shares by up to 1% [26] - Aored plans to reduce holdings of repurchased shares by up to 1.29% [27] Group 8 - Xianhe Co. plans to raise up to 3 billion yuan through a private placement for a new materials project [34] - Guanshi Technology plans to raise up to 700 million yuan for photomask manufacturing and other projects [33] - Beilu Pharmaceutical plans to raise up to 300 million yuan for production facility upgrades and working capital [34]

康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 海外監管公告 本 公 告 乃 康 希 諾 生 物 股 份 公 司（「本公司」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市規則第13.10B條而發表。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 發 的《康 希 諾 生 物 股 份 公 司 第 三 屆 董 事 會 第 二 次 臨 時 會 議 決 議 公 告》《康 希 諾 生 物 股 份 公 司 第 三 屆 監 事 會 第 九 次 會 議 決 議 公 告》《康 希 諾 生 物 股 份 公 司2025年A股 限 制 性 股 票 激 勵 計 劃（草 案）摘 要 公 告》 《康希諾生物股份公司關於註銷回購A股 股 份 並 減 少 註 冊 資 本 的 公 告》《康 希 諾 生 物股份公司關於召開2025年 第 一 次 臨 時 股 東 大 會 的 通 知》《康 希 諾 生 物 股 份 公 司 2025年A股 限 制 性 股 票 激 勵 計 劃（草 案）》《康 希 諾 生 物 股 份 公 司2025年A股限制性 股 票 激 勵 計 劃 實 施 ...

Major Events - Baiyun Airport announced a joint investment with China Duty Free Group to establish a duty-free company at Guangzhou Baiyun Airport with a registered capital of 45 million yuan, where China Duty Free will contribute 22.95 million yuan for a 51% stake [4] - Dongxing Medical plans to acquire 90% of Wuhan Yijiaobao's equity for cash, which is expected to constitute a major asset restructuring [5] - Fosun Pharma's subsidiary is planning to transfer 100% of Shanghai Clon to enhance asset operation efficiency, with a transaction value of up to 1.256 billion yuan [7] - Hengxing Technology's subsidiary is undergoing a review for the extension of mining license for Longtoushan Gold Mine, with exploration activities ongoing [8] - New Sai Co.'s general manager Chen Jianjiang resigned due to work adjustments [9] - Hailiang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange, with details yet to be finalized [10] - Zhejiang University Net announced plans to sell 48.6 million shares of Wanliyang, expecting a transaction amount of 475 million yuan [11] - Huazhong Precision terminated its plan to issue A-shares to specific investors, which also halts the acquisition of control by a third party [12] - Jiazhe New Energy stated that its green chemical business is not yet commercially viable [13] Significant Contracts - Haitai Development's subsidiary signed a property sale contract worth 440 million yuan, expected to increase profits by approximately 62.86 million yuan in 2025 [18] - Dongjie Intelligent's overseas subsidiary received a procurement order worth approximately 180 million yuan, accounting for 22.3% of the company's audited revenue for 2024 [19][20] - Zhiguang Electric's subsidiary signed a procurement contract worth 164 million yuan for energy storage systems [21] - ST Songfa's subsidiary signed contracts for building four oil tankers, with a total value between 400 million to 600 million USD [22] - Huaguang Huaneng signed a sales contract for waste heat boilers worth 160 million yuan for a power plant project in Cambodia [23] - Keda Intelligent plans to issue H-shares and list on the Hong Kong Stock Exchange, with details still under discussion [24] Shareholding Changes - Zai Sheng Technology's controlling shareholder plans to reduce holdings by up to 3% [28] - Compton plans to reduce up to 1% of its repurchased shares [29] - Aorede plans to reduce up to 1.29% of its shares from the repurchased stock [30] - Yidian Tianxia's controlling shareholder plans to reduce up to 3% of its shares [31] - Huace Film's shareholders plan to transfer 3.6% of the company's shares through an inquiry transfer [32] Buybacks and Financing - Qibin Group obtained a special financing support of up to 90 million yuan for share repurchase [33] - CanSino plans to cancel 406,100 repurchased shares and reduce registered capital accordingly [35] Fundraising Initiatives - Xianhe Co. plans to raise up to 3 billion yuan through a private placement for a high-performance paper-based new materials project [36] - Guanshi Technology plans to raise up to 700 million yuan for photomask manufacturing and other projects [37] - Beilu Pharmaceutical plans to raise up to 300 million yuan for production line upgrades and working capital [38]

格隆汇9月26日丨康希诺(688185.SH)公布2025年A股限制性股票激励计划，本激励计划拟向激励对象授 予258万股限制性股票，约占本激励计划草案公告时公司股本总额的1.04%。其中首次授予206.55万股， 约占本激励计划草案公告时公司股本总额的0.83%，首次授予部分占本次授予权益总额的80.06%；预留 51.45万股，约占本激励计划草案公告时公司股本总额的0.21%，预留部分占本次授予权益总额的 19.94%。 MACD金叉信号形成，这些股涨势不错！ ...

智通财经APP讯，康希诺(688185.SH)披露2025年A股限制性股票激励计划(草案)，拟向激励对象授予258 万股限制性股票，约占2025年A股激励计划草案公告时公司股本总额的1.04%。其中首次授予206.55万 股，首次授予的激励对象人数共计87人，授予价格(含预留)为41.20元/股。 ...

注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均未超过公司总 股本的 1.00%。公司全部有效的激励计划所涉及的标的股票总数累计不超过股权激励计划提交股东大会时 公司股本总额的 10.00%。 康希诺生物股份公司 2025 年 A 股限制性股票激励计划首次授予激励对象名单 2025 年 9 月 26 日 2、本计划激励对象不包括独立非执行董事、监事，也不包括单独或合计持有上市公司 5%以上股份的 股东、上市公司实际控制人及其配偶、父母、子女。 序号 姓名 国籍 职务 获授的限制 性股票数量 （股） 占授予限 制性股票 总数的比 例 占 2025 年 A 股激励计划 草案公告日 股本总额的 比例 一、首次授予部分 董事、高级管理人员 1 王靖 中国 执行董事、副总经理 103,700 4.02% 0.04% 2 崔进 中国 董事会秘书 46,300 1.79% 0.02% 董事会认为需要激励的其他人员 （中国籍共 81 人） 1,771,900 68.68% 0.72% 董事会认为需要激励的其他人员 （外籍及中国香港籍共 4 人） 143,600 5.57% 0.06% 首次授予部 ...

证券代码：688185 证券简称：康希诺 公告编号：2025-025 康希诺生物股份公司 2025 年 A 股限制性股票激励计划（草案）摘要公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 股权激励方式：限制性股票（第二类） 股份来源：康希诺生物股份公司（以下简称"公司"或"本公司"）从 二级市场回购或/和向激励对象定向发行公司 A 股普通股股票。 股权激励的权益总数及涉及的标的股票总数：《康希诺生物股份公司 2025 年 A 股限制性股票激励计划（草案）》（以下简称"本激励计划"或"本计划"） 拟向激励对象授予 2,580,000 股限制性股票，约占本激励计划草案公告时公司股 本总额 247,449,899 股的 1.04%。其中首次授予 2,065,500 股，约占本激励计划草 案公告时公司股本总额的 0.83%，首次授予部分占本次授予权益总额的 80.06%； 预留 514,500 股，约占本激励计划草案公告时公司股本总额的 0.21%，预留部分 占本次授予权益总额的 19.94%。 一、股权激 ...